Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer.
from EurekAlert! - Breaking News https://ift.tt/2CrLqLZ
via IFTTT
Wednesday, March 13, 2019
Adding docetaxel-based chemotherapy to standard treatment for high-risk prostate cancer
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.